However, oncogenic mutations in the gene PIK3CA, which encodes the p110α catalytic subunit of PI3K, were found in five out of six cancer cell lines exhibiting enhanced sensitivity to RNMT inhibition (figures 1 and 6, and table 1). The gene discussed is PIK3CA; the disease is cancer.